Amicus Therapeutics, Inc (FOLD) is a publicly traded Healthcare sector company. As of May 20, 2026, FOLD trades at $14.49 with a market cap of $4.55B and a P/E ratio of -161.00. FOLD moved +0.00% today. Year to date, FOLD is +47.11%; over the trailing twelve months it is +101.25%. Its 52-week range spans $5.51 to $14.50. Analyst consensus is buy with an average price target of $14.50. Rallies surfaces FOLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioMarin Completes $4.8bn Amicus Acquisition Adding Two Rare Disease Drugs: BioMarin has completed its $4.8bn acquisition of Amicus Therapeutics at $14.50 per share, adding Galafold and the Pombiliti+Opfolda combination for Fabry and Pompe diseases. The deal also secures US rights to the Phase III FSGS candidate DMX-200, broadening BioMarin’s rare disease portfolio.
| Metric | Value |
|---|---|
| Price | $14.49 |
| Market Cap | $4.55B |
| P/E Ratio | -161.00 |
| EPS | $-0.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.50 |
| 52-Week Low | $5.51 |
| Volume | 5.29M |
| Avg Volume | 0 |
| Revenue (TTM) | $634.21M |
| Net Income | $-27.11M |
| Gross Margin | 88.50% |
24 analysts cover FOLD: 0 strong buy, 16 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.50.